Cognition and memory enhancement drugs market size is predicted to witness high growth rate between 2022 and 2027. This high growth rate can be attributed to its utilization in treatment of multiple disorders including schizophrenia, attention deficit hyperactivity disorder, stroke, Alzheimer’s disease, ageing, etc.
The Global Cognition and Memory Enhancement Drugs Market is projected to reach US$ 9200 million by 2028, growing at a CAGR of 8.5%.
Upsurge in geriatric population along with increasing prevalence of neurological & memory-related disorders will drive the cogition and memory enhancement drugs industry revenue generation over the forecast period. However, ethical issues relevant to the usage of such drugs may hamper the industry growth till 2027.
Global cognition and memory enhancement drugs market is segmented based on the product as, Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall. On the basis of application, the global cognition and memory enhancement drugs market is segregated as Disease Treatment, Academic Performance, Athletic Performance. Disease treatment is expected to witness notable gains in the forecast years.
Global cognition and memory enhancement drugs market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional cognition and memory enhancement drugs market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Global cognition and memory enhancement drugs market share consists of several players including Pfizer, Novartis, AlternaScript, Shire Pharmaceuticals, Takeda Pharmaceutical Company, Allergan plc, Eisai, Barr Pharmaceuticals, Johnson & Johnson and Cephalon.
The Cognition and Memory Enhancement Drugs Market has been segmented as below:
Cognition and Memory Enhancement Drugs Market, By Product
Cognition and Memory Enhancement Drugs Market, By Application
Cognition and Memory Enhancement Drugs Market, By Region
The report covers:
Report scope:
The global cognition and memory enhancement drugs market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends.
The report scope includes market analysis on regional as well as country level. The report also provides competitive landscape covering company market shares with detailed profiling for major revenue contributing companies.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer, Novartis, AlternaScript, Shire Pharmaceuticals, Takeda Pharmaceutical Company, Allergan plc, Eisai, Barr Pharmaceuticals, Johnson & Johnson and Cephalon.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
Robotic Pharmacy Prescription Dispensing Systems Market
Laboratory Information Management System Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rapidly aging population
4.2.2. High incidence of neurodegenerative disorders
4.2.3. Benefits of smart drugs
4.3. Restraints
4.3.1. Ethical issues
4.4. Opportunities
4.4.1. Effective strength of the drugs
4.5. Challenges
4.5.1. Trade policies
5. Cognition and Memory Enhancement Drugs Market, By Product
5.1. Key Points
5.2. Aricept
5.3. Razadyne
5.4. Namenda
5.5. Exelon
5.6. Provigil
5.7. Ritalin
5.8. Adderall
5.9. Others
6. Cognition and Memory Enhancement Drugs Market, By Application
6.1. Key Points
6.2. Disease treatment
6.2.1. Developmental conditions
6.2.2. Neurodegenerative disorders
6.3. Academic performance
6.4. Athletic performance
6.5. Others
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Pfizer
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Novartis
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. AlternaScript
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Shire Pharmaceuticals
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Takeda Pharmaceutical Company
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Allergan plc
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Eisai, Barr Pharmaceuticals
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Johnson & Johnson
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. Cephalon
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
The Cognition and Memory Enhancement Drugs Market has been segmented as below:
Cognition and Memory Enhancement Drugs Market, By Product
Cognition and Memory Enhancement Drugs Market, By Application
Cognition and Memory Enhancement Drugs Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
